173 related articles for article (PubMed ID: 20492726)
1. Methylation status of DDIT3 gene in chronic myeloid leukemia.
Wang YL; Qian J; Lin J; Yao DM; Qian Z; Zhu ZH; Li JY
J Exp Clin Cancer Res; 2010 May; 29(1):54. PubMed ID: 20492726
[TBL] [Abstract][Full Text] [Related]
2. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
3. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome.
Lin J; Wang YL; Qian J; Yao DM; Zhu ZH; Qian Z; Xu WR
Leuk Res; 2010 Aug; 34(8):991-4. PubMed ID: 20116099
[TBL] [Abstract][Full Text] [Related]
5. GPX3 promoter is methylated in chronic myeloid leukemia.
Yao DM; Zhou JD; Zhang YY; Yang L; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Int J Clin Exp Pathol; 2015; 8(6):6450-7. PubMed ID: 26261521
[TBL] [Abstract][Full Text] [Related]
6. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Zion M; Ben-Yehuda D; Avraham A; Cohen O; Wetzler M; Melloul D; Ben-Neriah Y
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10722-6. PubMed ID: 7938018
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Modulation of DDIT3 and MGMT Expression Acts Synergistically with Resistance to Imatinib towards CML Disease Progression: A Hospital based Study.
Hazarika G; Kalita MJ; Kalita S; Das PP; Dutta K; Lahkar L; Rajkonwar A; Idris MG; Khamo V; Kusre G; Medhi S
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4059-4069. PubMed ID: 38156838
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
[TBL] [Abstract][Full Text] [Related]
10. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
Vatanmakanian M; Tavallaie M; Ghadami S
Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
[TBL] [Abstract][Full Text] [Related]
11. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Study of SCIN Expression and Dromoter Methylation in Patients with Chronic Myeloid Leukemia].
Zhang ZH; Lian XY; Li XX; He PF; Lin J; Qian J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):646-651. PubMed ID: 31204912
[TBL] [Abstract][Full Text] [Related]
13. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
[TBL] [Abstract][Full Text] [Related]
14. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
[TBL] [Abstract][Full Text] [Related]
15. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
16. [Methylation of miR-378 in Chronic Myeloid Leukemia].
Wu DH; Yang J; Yang L; Wen XM; Guo H; Yao DM; Lin J; Zhang YY; Zhang M; Deng ZQ; Qian J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):61-5. PubMed ID: 26913395
[TBL] [Abstract][Full Text] [Related]
17. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia.
Della Peruta M; Martinelli G; Moratti E; Pintani D; Vezzalini M; Mafficini A; Grafone T; Iacobucci I; Soverini S; Murineddu M; Vinante F; Tecchio C; Piras G; Gabbas A; Monne M; Sorio C
Cancer Res; 2010 Nov; 70(21):8896-906. PubMed ID: 20959494
[TBL] [Abstract][Full Text] [Related]
18. [SHP-1 gene in the disease progression of chronic myeloid leukemia].
Li Y; Wang X; Yang L; Pan Y; Shang Y; Luo J
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1074-8. PubMed ID: 25543700
[TBL] [Abstract][Full Text] [Related]
19. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
[TBL] [Abstract][Full Text] [Related]
20. Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients.
Al-Achkar W; Moassass F; Youssef N; Wafa A
J BUON; 2016; 21(2):444-9. PubMed ID: 27273956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
